NO20070956L - Tumonnalsokende celler konstruert for a produsere tumornekrosefaktor-beslektet apoptoseinduscrende ligand (TRAIL) ved adenoviralmediert genoverforing. - Google Patents

Tumonnalsokende celler konstruert for a produsere tumornekrosefaktor-beslektet apoptoseinduscrende ligand (TRAIL) ved adenoviralmediert genoverforing.

Info

Publication number
NO20070956L
NO20070956L NO20070956A NO20070956A NO20070956L NO 20070956 L NO20070956 L NO 20070956L NO 20070956 A NO20070956 A NO 20070956A NO 20070956 A NO20070956 A NO 20070956A NO 20070956 L NO20070956 L NO 20070956L
Authority
NO
Norway
Prior art keywords
tumor
necrosis factor
adenoviral
trail
inducing ligand
Prior art date
Application number
NO20070956A
Other languages
English (en)
Norwegian (no)
Inventor
Francesco Colotta
Alessandro Massimo Gianni
Carmelo Carlo Stella
Original Assignee
Dompe Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Spa filed Critical Dompe Spa
Publication of NO20070956L publication Critical patent/NO20070956L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464436—Cytokines
    • A61K39/464438—Tumor necrosis factors [TNF], CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49—Breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/48—Regulators of apoptosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20070956A 2004-07-29 2007-02-20 Tumonnalsokende celler konstruert for a produsere tumornekrosefaktor-beslektet apoptoseinduscrende ligand (TRAIL) ved adenoviralmediert genoverforing. NO20070956L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04017907A EP1621550A1 (en) 2004-07-29 2004-07-29 Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
PCT/EP2005/007957 WO2006010558A1 (en) 2004-07-29 2005-07-21 Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (trail)

Publications (1)

Publication Number Publication Date
NO20070956L true NO20070956L (no) 2007-02-20

Family

ID=34925971

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070956A NO20070956L (no) 2004-07-29 2007-02-20 Tumonnalsokende celler konstruert for a produsere tumornekrosefaktor-beslektet apoptoseinduscrende ligand (TRAIL) ved adenoviralmediert genoverforing.

Country Status (25)

Country Link
US (1) US20070264231A1 (ja)
EP (2) EP1621550A1 (ja)
JP (1) JP5042826B2 (ja)
KR (1) KR20070047757A (ja)
CN (1) CN101076540B (ja)
AT (1) ATE455847T1 (ja)
AU (1) AU2005266543B2 (ja)
BR (1) BRPI0513855A (ja)
CA (1) CA2571426A1 (ja)
DE (1) DE602005019050D1 (ja)
DK (1) DK1771468T3 (ja)
ES (1) ES2340400T3 (ja)
HK (1) HK1110874A1 (ja)
HR (1) HRP20100227T1 (ja)
IL (1) IL180233A (ja)
MX (1) MX2007001152A (ja)
NO (1) NO20070956L (ja)
NZ (1) NZ552223A (ja)
PL (1) PL1771468T3 (ja)
PT (1) PT1771468E (ja)
RS (1) RS51381B (ja)
RU (1) RU2390558C2 (ja)
SI (1) SI1771468T1 (ja)
WO (1) WO2006010558A1 (ja)
ZA (1) ZA200701231B (ja)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200610134B (en) * 2004-06-18 2008-06-25 Genentech Inc Use of Apo2L receptor agonists and NK cells or NK cell activators
DE102006020307A1 (de) * 2006-05-03 2007-11-08 Martin-Luther-Universität Halle-Wittenberg TNF-related apoptosis-including (TRAIL)stabil transgen exprimierende mesenchymale Stammzellen, Verfahren zu ihrer Herstellung und zu ihrer Verwendung
WO2008142862A1 (ja) * 2007-05-18 2008-11-27 National University Corporation Asahikawa Medical College 血管内皮前駆細胞の移植による抗がん療法
CN102154213B (zh) * 2011-01-19 2012-07-25 郑骏年 一种运载荷载细胞因子的双调控溶瘤腺病毒的新型cik细胞
JP2015506697A (ja) * 2012-02-01 2015-03-05 ポステック アカデミー‐インダストリー ファウンデーション １２量体ｔｒａｉｌ及びｈｓｖ−ｔｋ自殺遺伝子を同時に発現するベクター並びにそれを用いた抗癌幹細胞治療剤
CN103288966B (zh) * 2013-05-17 2015-01-21 华侨大学 一种融合受体及其用于治疗大肠癌的基因药物
RU2552609C1 (ru) * 2013-10-28 2015-06-10 Федеральное государственное бюджетное учреждение науки Институт молекулярной биотехнологии им. В.А. Энгельгардта Российской академии наук (ИМБ РАН) Способ получения системы направленной доставки белковых молекул (онколитических белков) в опухолевые ткани на основе активированных лимфоцитов
EP3209382B1 (en) 2014-10-24 2020-11-25 Calidi Biotherapeutics, Inc. Combination immunotherapy approach for treatment of cancer
ES2939084T3 (es) * 2015-07-29 2023-04-18 Onk Therapeutics Ltd Células asesinas naturales y líneas de células asesinas naturales modificadas que tienen citotoxicidad aumentada
US10906951B2 (en) * 2015-07-29 2021-02-02 Onk Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
CN112469816A (zh) * 2018-06-06 2021-03-09 加拿大干细胞技术公司 用于富集髓系来源的抑制细胞的试剂盒、组合物和方法
US20220143089A1 (en) * 2019-03-21 2022-05-12 Onk Therapeutics Limited Modified immune effector cells with increased resistance to cell death
EP3712257A1 (en) 2019-03-21 2020-09-23 ONK Therapeutics Limited Modified natural killer cells with increased resistance to cell death
WO2021209625A1 (en) 2020-04-17 2021-10-21 Onk Therapeutics Limited High potency natural killer cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2292760A1 (en) * 1997-06-04 1998-12-10 Oxford Biomedica (Uk) Limited Vector
JP2004526666A (ja) * 2000-09-11 2004-09-02 マスク ファウンデーション フォー リサーチ デヴェロップメント アポトーシスの選択的誘導によって腫瘍を治療するための組成物及び方法
CA2426659A1 (en) * 2000-10-24 2002-08-29 Immunex Corporation Method for treatment of tumors using combination therapy
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
JP4493882B2 (ja) * 2001-06-19 2010-06-30 株式会社カネカ 抗原およびこの抗原を識別するモノクローナル抗体

Also Published As

Publication number Publication date
EP1621550A1 (en) 2006-02-01
WO2006010558A8 (en) 2006-08-24
BRPI0513855A (pt) 2008-05-20
JP2008507961A (ja) 2008-03-21
AU2005266543B2 (en) 2012-02-02
US20070264231A1 (en) 2007-11-15
DE602005019050D1 (de) 2010-03-11
RU2007107369A (ru) 2008-09-10
SI1771468T1 (sl) 2010-07-30
ZA200701231B (en) 2008-08-27
EP1771468A1 (en) 2007-04-11
PT1771468E (pt) 2010-04-20
EP1771468B1 (en) 2010-01-20
DK1771468T3 (da) 2010-05-25
RS51381B (en) 2011-02-28
CN101076540A (zh) 2007-11-21
IL180233A0 (en) 2007-07-04
IL180233A (en) 2010-12-30
ES2340400T3 (es) 2010-06-02
HRP20100227T1 (hr) 2010-07-31
WO2006010558A1 (en) 2006-02-02
JP5042826B2 (ja) 2012-10-03
MX2007001152A (es) 2007-04-18
CA2571426A1 (en) 2006-02-02
RU2390558C2 (ru) 2010-05-27
ATE455847T1 (de) 2010-02-15
CN101076540B (zh) 2012-10-24
HK1110874A1 (en) 2008-07-25
AU2005266543A1 (en) 2006-02-02
KR20070047757A (ko) 2007-05-07
PL1771468T3 (pl) 2010-07-30
NZ552223A (en) 2009-01-31

Similar Documents

Publication Publication Date Title
NO20070956L (no) Tumonnalsokende celler konstruert for a produsere tumornekrosefaktor-beslektet apoptoseinduscrende ligand (TRAIL) ved adenoviralmediert genoverforing.
TW200611974A (en) Chimeric adenoviruses for use in cancer treatment
WO2009046141A3 (en) Antisense modulation of fibroblast growth factor receptor 4 expression
MX2010003321A (es) Polipeptidos y polinucleotidos del fago qmru y sus usos.
TW200740841A (en) Polypeptides having antimicrobial activity and polynucleotides encoding same
EP1824872A4 (en) RNAI MODULATION OF MLL-AF4 AND USES THEREOF
EP4242236A3 (en) Monoclonal antibodies against claudin-18 for treatment of cancer
MX2009012846A (es) Polipeptidos que tienen actividad celulosica mejorada y polinucleotidos que los codifican.
WO2005023824A3 (en) Methods for inhibiting tumor cell proliferation
EA200702682A1 (ru) Устойчивая к sclerotinia brassica и способы развития устойчивости к sclerotinia
IL189452A0 (en) Therapy with cd4 binding peptides and radiation
WO2007014077A3 (en) Rnai modulation of the rho-a gene and uses thereof
WO2009048769A3 (en) Vaccinia virus h3l and b5r specific monoclonal antibodies and methods of making and using same
MX2007005520A (es) Polipeptidos que tienen actividad antimicrobiana y polinucleotidos que codifican los mismos.
TW200734350A (en) Polypeptides having antimicrobial activity and polynucleotides encoding same
WO2012031137A3 (en) Vesicular stomatitis viruses
WO2020207510A3 (zh) 基因在促进水稻籽粒产量上的应用
WO2008133137A1 (ja) 遺伝子治療のためのベクター
WO2008067025A3 (en) Oncolytic adenoviruses and uses thereof
WO2005079490A3 (en) Methods of therapy and diagnosis using targeting of cells that express steap2 polypeptides
WO2005014607A3 (en) Antisense modulation of stearoyl-coa desaturase expression
TW200621285A (en) Polypeptides having antimicrobial activity and polyncleotides encoding same
GB0517292D0 (en) Cell migration modulating compounds
WO2008037490A3 (en) Galactosyltransferase
WO2008069940A3 (en) Multi-microrna methods and compositions

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application